Beta Bionics (NASDAQ: BBNX) shares preliminary Q4 2025 topline results

Rhea-AI Filing Summary

Beta Bionics, Inc. filed a current report to disclose that it has issued a press release with preliminary, unaudited fourth quarter 2025 topline financial results and key operating metrics. The company furnished this information under its results of operations and financial condition disclosure and attached the press release as Exhibit 99.1. The report clarifies that these materials are being furnished rather than filed, which affects how they are treated under securities law.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

False000167463200016746322026-01-082026-01-08iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 8, 2026

_______________________________

Beta Bionics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-42491	47-5386878
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

11 Hughes

Irvine, California 92618

(Address of Principal Executive Offices) (Zip Code)

(949) 427-7785

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	BBNX	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 8, 2026, Beta Bionics, Inc. (the “Company”) issued a press release announcing its preliminary, unaudited fourth quarter 2025 topline financial results and key metrics. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d)       Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 8, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Beta Bionics, Inc.
Date: January 8, 2026	By:	/s/ Sean Saint
		Sean Saint
		President and Chief Executive Officer

FAQ

What did Beta Bionics (BBNX) disclose in this 8-K filing?

Beta Bionics disclosed that it issued a press release containing its preliminary, unaudited fourth quarter 2025 topline financial results and key metrics, furnished as Exhibit 99.1.

Which period’s results are covered by Beta Bionics’ latest update?

The update covers Beta Bionics’ preliminary, unaudited topline financial results and key metrics for the fourth quarter of 2025.

How did Beta Bionics provide its preliminary Q4 2025 results?

Beta Bionics provided its preliminary Q4 2025 topline results and key metrics through a press release dated January 8, 2026, which is attached to the report as Exhibit 99.1.

Are the Q4 2025 results for Beta Bionics audited?

No. The company describes the fourth quarter 2025 topline financial results and key metrics in the press release as preliminary and unaudited.

Is the Beta Bionics Q4 2025 press release considered filed with the SEC?

The company states that the information under the results of operations item, including Exhibit 99.1, is furnished and not deemed filed or subject to Section 18 liability, unless specifically incorporated by reference in another filing.

What exhibits are included with this Beta Bionics (BBNX) report?

The report includes Exhibit 99.1, a press release dated January 8, 2026, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the latest Beta Bionics current report?

The report was signed on behalf of Beta Bionics, Inc. by Sean Saint, its President and Chief Executive Officer.